The launch of Lundbeck’s oral alcohol dependence treatment, Selincro, on the important German market gives the small Finnish company Biotie a milestone payment of EUR 2 million. The Finnish company writes in a press release.

The release also reveals that Lundbeck will continue the roll-out on additional European markets during 2014.

Britain’s National Institute for Health and Care Excellence (NICE) has previously turned its thumbs up to Selincro. In Denmark, the Danish Health and Medicines Authority denied giving general reimbursement to the pill last year, saying there was a risk that doctors would prescribe Selincro to patients without ensuring proper treatment, including psychosocial support and counseling.

Sales of the alcohol-fighting pill has been hugely disappointing in Denmark so far. Acoording to Biotie, Lundbeck has so far launched Selincro on more than 20n European markets.

 IRF unimpressed by Lundbeck and Novo 

 Lundbeck launches alcohol pill in Denmark 

 Lundbeck’s alcohol pill hits speed bump 

 Lundbeck launches alcohol pill in UK 

- translated by Martin Havtorn Petersen

Would you like to receive the latest news from Medwatch directly in your e-mail inbox? Sign up for our free english newsletter below.